Inhibikase Therapeutics (NASDAQ: IKT) is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders. The company's lead program targets the c-Abl tyrosine kinase pathway, which has been implicated in neuronal dysfunction and alpha-synuclein pathology in Parkinson's disease. [1]
| Attribute | Details |
|---|---|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2010 |
| CEO | Milton Werner, PhD |
| Market Cap | ~$50 million (2024) |
| Employees | ~20 |
| Ticker | NASDAQ: IKT |
Inhibikase's platform targets the c-Abl tyrosine kinase pathway, which is activated in response to cellular stress in neurodegenerative diseases:
The company uses structure-based drug design to develop brain-penetrant c-Abl inhibitors optimized for CNS delivery.
IkT-148009 is a potent, selective c-Abl tyrosine kinase inhibitor designed for once-daily oral dosing.
| Attribute | Details |
|---|---|
| Mechanism | c-Abl kinase inhibition |
| Target | Activated c-Abl in dopaminergic neurons |
| Phase | Phase 2 |
| Indication | Parkinson's disease |
| Administration | Oral (tablet) |
| Status | Enrolling |
c-Abl activation contributes to Parkinson's disease pathology through multiple mechanisms: [2]
| Drug | Target | Indication | Stage |
|---|---|---|---|
| IkT-148009 | c-Abl | Parkinson's disease | Phase 2 |
| IkT-148x | c-Abl | Multiple system atrophy | Preclinical |
| Undisclosed | Parkinson's disease | Additional targets | Discovery |
The c-Abl tyrosine kinase has emerged as a therapeutic target in neurodegenerative diseases:
| Year | Event | Amount |
|---|---|---|
| 2010 | Series A | $10M |
| 2015 | Series B | $15M |
| 2019 | Series C | $25M |
| 2021 | IPO | $40M |
Inhibikase is the leading c-Abl inhibitor in clinical development for Parkinson's disease:
| Company | Drug | Target | Status |
|---|---|---|---|
| Inhibikase | IkT-148009 | c-Abl | Phase 2 |
| Novartis | Nilotinib | c-Abl | Phase 2 (repurposed) |
| Neuraly | NLY01 | GLP-1 | Phase 2 |